- Home
- XMTR vs AKBA Comparison
XMTR vs AKBA Comparison
Compare XMTR & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XMTR
- AKBA
- Stock Information
- Founded
- XMTR 2013
- AKBA 2007
- Country
- XMTR United States
- AKBA United States
- Employees
- XMTR N/A
- AKBA N/A
- Industry
- XMTR Industrial Machinery/Components
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- XMTR Technology
- AKBA Health Care
- Exchange
- XMTR Nasdaq
- AKBA Nasdaq
- Market Cap
- XMTR 1.1B
- AKBA 958.6M
- IPO Year
- XMTR 2021
- AKBA 2014
- Fundamental
- Price
- XMTR $32.45
- AKBA $3.68
- Analyst Decision
- XMTR Buy
- AKBA Strong Buy
- Analyst Count
- XMTR 11
- AKBA 5
- Target Price
- XMTR $34.82
- AKBA $6.90
- AVG Volume (30 Days)
- XMTR 747.9K
- AKBA 6.4M
- Earning Date
- XMTR 08-07-2025
- AKBA 08-07-2025
- Dividend Yield
- XMTR N/A
- AKBA N/A
- EPS Growth
- XMTR N/A
- AKBA N/A
- EPS
- XMTR N/A
- AKBA N/A
- Revenue
- XMTR $573,810,000.00
- AKBA $184,909,000.00
- Revenue This Year
- XMTR $21.56
- AKBA $26.88
- Revenue Next Year
- XMTR $17.54
- AKBA $44.34
- P/E Ratio
- XMTR N/A
- AKBA N/A
- Revenue Growth
- XMTR 19.35
- AKBA N/A
- 52 Week Low
- XMTR $11.08
- AKBA $0.80
- 52 Week High
- XMTR $45.33
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- XMTR 50.74
- AKBA 64.49
- Support Level
- XMTR $29.60
- AKBA $3.46
- Resistance Level
- XMTR $37.72
- AKBA $3.98
- Average True Range (ATR)
- XMTR 1.89
- AKBA 0.25
- MACD
- XMTR -0.52
- AKBA -0.04
- Stochastic Oscillator
- XMTR 35.10
- AKBA 64.20
About XMTR Xometry Inc.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.